Takara Bio USA Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile
- GDPH203919D
- Pages: 21
- May 2017
- Total Views:1152
- Region : North America
- GlobalData
- Equity Research Report

Details
Summary
Takara Bio USA Inc (Takara Bio USA), formerly Clontech Laboratories, Inc. is a subsidiary of Takara Bio Inc is a healthcare company that provides kits, reagents, and services to researchers. The company's products include adenoviral transduction tools, adenoviral vector systems, apoptosis kits, cdna synthesis kits, cell biology kits, cloning enhancer, cloning kits, cloning vectors, competent cells and detection of tagged proteins. It offers epigenetics kits, fluorescent protein antibodies, fluorescent proteins, gene expression profiling, lentiviral transduction tools, lentiviral vector systems, microrna transfection, mrna amplification and mutagenesis reagents, among others. Takara Bio USA products find applications in cell biology, cell culture, epigenetics, inducible systems, nucleic acid purification, protein interactions and viral transduction. The company also provides contract research services. It offers products in different parts of the US. Takara Bio USA is headquartered in Mountain View, California, the US.
Takara Bio USA Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
Business Description-A brief description of the company's operations.
Key Employees-A list of the key executives of the company.
Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors-A list of the key competitors of the company.
Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Takara Bio USA Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Takara Bio USA Inc, Medical Devices Deals, 2011 to YTD 2017 9
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 11
Licensing Agreements 12
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 12
ARIAD Pharma Enters Into Licensing Agreement With Clontech Labs 13
Takara Bio USA Inc-Key Competitors 15
Key Employees 16
Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product News 18
Feb 29, 2016: Clontech Laboratories Releases TaKaRa Taq Hot Start Version GMP Grade 18
Jan 20, 2016: Clontech Laboratories to Release a Highly Sensitive Kit for Human T-Cell Receptor Repertoire Analysis 19
Jan 11, 2016: Clontech Laboratories Releases a New Powerful Delivery Technology for CRISPR/Cas9-Mediated Gene Editing 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21
List Of Figure
List of Figures
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Takara Bio USA Inc, Medical Devices Deals, 2011 to YTD 2017 9
List Of Table
List of Tables
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Key Facts 1
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Takara Bio USA Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Takara Bio USA Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Takara Bio USA Inc, Medical Devices Deals, 2011 to YTD 2017 9
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 11
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 12
ARIAD Pharma Enters Into Licensing Agreement With Clontech Labs 13
Takara Bio USA Inc, Key Competitors 15
Takara Bio USA Inc, Key Employees 16
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Takara Bio USA Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Takara Bio USA Inc (Takara Bio USA), formerly Clontech Laboratories, Inc. is a subsidiary of Takara Bio Inc is a healthcare company that provides kits, reagents, and services to researchers. The company's products include adenoviral transduction tools, adenoviral vector systems, apoptosis kits, cdna synthesis kits, cell biology kits, cloning enhancer, cloning kits, cloning vectors, competent cells and detection of tagged proteins. It offers epigenetics kits, fluorescent protein antibodies, fluorescent proteins, gene expression profiling, lentiviral transduction tools, lentiviral vector systems, microrna transfection, mrna amplification and mutagenesis reagents, among others. Takara Bio USA products find applications in cell biology, cell culture, epigenetics, inducible systems, nucleic acid purification, protein interactions and viral transduction. The company also provides contract research services. It offers products in different parts of the US. Takara Bio USA is headquartered in Mountain View, California, the US.
Takara Bio USA Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
Business Description-A brief description of the company's operations.
Key Employees-A list of the key executives of the company.
Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors-A list of the key competitors of the company.
Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Takara Bio USA Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Takara Bio USA Inc, Medical Devices Deals, 2011 to YTD 2017 9
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 11
Licensing Agreements 12
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 12
ARIAD Pharma Enters Into Licensing Agreement With Clontech Labs 13
Takara Bio USA Inc-Key Competitors 15
Key Employees 16
Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product News 18
Feb 29, 2016: Clontech Laboratories Releases TaKaRa Taq Hot Start Version GMP Grade 18
Jan 20, 2016: Clontech Laboratories to Release a Highly Sensitive Kit for Human T-Cell Receptor Repertoire Analysis 19
Jan 11, 2016: Clontech Laboratories Releases a New Powerful Delivery Technology for CRISPR/Cas9-Mediated Gene Editing 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21
List Of Figure
List of Figures
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Takara Bio USA Inc, Medical Devices Deals, 2011 to YTD 2017 9
List Of Table
List of Tables
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Key Facts 1
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Takara Bio USA Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Takara Bio USA Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Takara Bio USA Inc, Medical Devices Deals, 2011 to YTD 2017 9
Takara Bio USA Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 11
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 12
ARIAD Pharma Enters Into Licensing Agreement With Clontech Labs 13
Takara Bio USA Inc, Key Competitors 15
Takara Bio USA Inc, Key Employees 16
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Takara Bio USA Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.